Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

GSK in $350 million deal to develop cancer drugs with UK biotech firm: FT

2/06/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzkvntgvntq5l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

GlaxoSmithKline Plc has agreed a deal worth more than $350 million with UK biotech company Adaptimmune to develop cancer drugs, the Financial Times reported on Monday.

London-based GSK, which sold its cancer drugs business to Swiss drugmaker Novartis in April, is expected to announce the deal on Monday, according to an FT report.

The newspaper said that GSK would pay Adaptimmune as much as $350 million over the next seven years, subject to development milestones being met.

Further payments would be due in subsequent years if GSK exercises all its options and targets continue to be met. In addition, Adaptimmune would receive sales royalties on any products that reach market, the financial daily reported.

The newspaper said GSK would develop cell-based cancer therapies that involve re-engineering patients’ white blood cells to improve the body’s ability to fight tumors.

The FT quoted James Noble, chief executive of Adaptimmune, as saying that the development work would be done at the company’s laboratories in Oxfordshire – boosting efforts to promote the so-called “golden triangle” around Oxford, Cambridge and London as a globally competitive biotech hub.

This article has been extracted from http://news.yahoo.com, please click on this link to read the article in full http://news.yahoo.com/gsk-350-million-deal-develop-cancer-drugs-uk-235742780–finance.html

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdkvmjkvmdgvmtmvmjkvmjgyl1vudgl0bgvkigrlc2lnbiaomjuplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Are PSLs a Blocker or an Enabler?

2017-10-02 11:00:00 +0100

The use of a Preferred Supplier List (PSL) was intended to support and strengthen relationships and performance between organisations and their third party suppliers. As the technical landscape continues to evolve at rapid rate recruitment and demand for new skills becomes more intense. Are PSLs still the solution or an obstacle to sourcing the right talent? The traditional PSL A dedicated list of partners intended to guarantee quality and availability ...

W1siziisijiwmtcvmdkvmjevmdgvndmvmduvmtmxl1vudgl0bgvkigrlc2lnbiaomjmplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Why do we punish the victims of hacking?

2017-09-21 09:00:00 +0100

Hacks occur every 39 seconds, with 95% of them targeting governments, retailers and the tech industry. If the hackers are caught, they'll face prison time under the Computer Misuse Act. More often than not, the businesses who are victims of those attacks expose themselves to punishment of their own. The laws that determine the duty of protection owed to businesses and their customers is both vague and broad, making them question just how much protection...